In all three studies mentioning this rare variant, researchers found that carriers had greatly reduced plasma Lp‐PLA2 activity but no significant difference in the risk of CHD compared with noncarriers.38, 77, 114 Another premature termination was observed at codon 63 due to an insertion of adenine at nucleotide 191 in exon 3 (Ins191), which would partly impair enzymatic function to a degree.111 Intron mutations were also assessed for their contribution to plasma Lp‐PLA2 level or disease progression. Here, PLA2G7 is linked to coronary artery disorder.